©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Crit Care Med. Nov 9, 2022; 11(6): 375-386
Published online Nov 9, 2022. doi: 10.5492/wjccm.v11.i6.375
Published online Nov 9, 2022. doi: 10.5492/wjccm.v11.i6.375
Postoperative complications and critical care management after cytoreduction surgery and hyperthermic intraperitoneal chemotherapy: A systematic review of the literature
Anjana S Wajekar, Sohan Lal Solanki, Vijaya P Patil, Department of Anaesthesiology, Critical Care and Pain, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai 400012, Maharashtra, India
Author contributions: Wajekar AS and Solanki SL helped in the literature review and writing of the manuscript; Wajekar AS, Solanki SL and Patil VP helped in editing the manuscript; all authors have read and approved the final manuscript.
Conflict-of-interest statement: All the authors declare that they have no conflict of interest.
PRISMA 2009 Checklist statement: The authors have read the PRISMA 2009 Checklist, and the manuscript was prepared and revised according to the PRISMA 2009 Checklist.
Corresponding author: Sohan Lal Solanki, MD, Professor, Department of Anaesthesiology, Critical Care and Pain, Tata Memorial Hospital, Homi Bhabha National Institute, 2nd Floor, Main Building, Tata Memorial Hospital, Dr E Borges Marg, Parel, Mumbai 400012, Maha
Received: March 13, 2022
Peer-review started: March 13, 2022
First decision: May 31, 2022
Revised: June 13, 2022
Accepted: September 9, 2022
Article in press: September 9, 2022
Published online: November 9, 2022
Processing time: 235 Days and 15.9 Hours
Peer-review started: March 13, 2022
First decision: May 31, 2022
Revised: June 13, 2022
Accepted: September 9, 2022
Article in press: September 9, 2022
Published online: November 9, 2022
Processing time: 235 Days and 15.9 Hours
Core Tip
Core Tip: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is a complex procedure with some life-threatening complications in the immediate postoperative period, reported morbidity rates between 12%-60% and a mortality rate of 0.9%-5.8%. There is an exaggerated metabolic and inflammatory response after surgery which may be termed as physiological in view of the nature of surgery combined with use of heated intraperitoneal chemotherapy.